ONO Pharmaceutical Enters Agreement with Seikagaku for Co-Development and Marketing of Gel-One in Japan, Currently in Phase III Trials

ONO Pharmaceutical Co. Ltd. has entered a definitive agreement with Seikagaku Corporation for the co-development and exclusive marketing of Gel-One, a treatment for osteoarthritis in Japan. The product is currently in Phase III clinical trials, focusing on knee and hip osteoarthritis. The collaboration aims to expedite the studies for timely manufacturing and marketing authorization. Ono will pay Seikagaku tiered royalties based on development and marketing progress.